Xadago (safinamide) for Parkinson’s disease
What is Xadago for Parkinson’s?
Xadago (safinamide) is an oral add-on therapy used to manage off episodes — periods in which motor symptoms fluctuate between medication doses — in people with Parkinson’s disease being treated with levodopa and carbidopa.
Motor symptoms in Parkinson’s arise due to a loss of the brain signaling chemical dopamine. The mainstay treatment is levodopa — a precursor that’s converted to dopamine in the brain — combined with carbidopa, a molecule that helps more levodopa reach the brain. Over time, however, this combination can become less effective, leading to off episodes. Higher levodopa doses cause side effects such as dyskinesia, or uncontrolled involuntary movements.
Xadago is a highly selective, reversible inhibitor of monoamine oxidase B (MAO-B), an enzyme that normally works to break down dopamine. As such, Xadago is thought to help prevent the degradation of dopamine to ease motor fluctuations for Parkinson’s patients who are using levodopa and carbidopa. It may also inhibit the release of glutamate, another molecule believed to contribute to Parkinson’s symptoms.
The MAO-B inhibitor was originally developed by Newron Pharmaceuticals. It is now marketed by Supernus Pharmaceuticals in the U.S. and Zambon in the European Union. In Canada, the medication is sold by Valeo Pharma under the brand name Onstryv.
Therapy snapshot
| Brand name | Xadago |
| Chemical name | Safinamide |
| Usage | Used to manage off episodes in Parkinson’s patients on levodopa and carbidopa |
| Administration | Oral tablets |
Who can take Xadago?
Xadago is approved in the U.S. as an add-on to levodopa/carbidopa for people with Parkinson’s who are experiencing off episodes. It holds similar approvals in the EU and Canada.
According to Xadago’s prescribing information, the medication is contraindicated, or should not be used, in people who:
- are using certain other medications, including other drugs that inhibit monoamine oxidase, as well as opioids, certain antidepressants, cyclobenzaprine, methylphenidate or amphetamine, St. John’s wort, or dextromethorphan
- have a history of immune reactions (hypersensitivity) to safinamide
- have severe liver impairment
Xadago is also not usually recommended for people with major psychotic disorders, as the medication could exacerbate symptoms.
How is Xadago administered?
Xadago is taken as a single oral tablet once daily at the same time of day, with or without food. The recommended Xadago dosage is 50 mg, which may be increased to 100 mg after two weeks if needed and tolerated.
A maximum dose of 50 mg is recommended for people with moderate liver impairment.

Xadago in clinical trials
The approval of Xadago for off episodes was largely supported by two Phase 3 clinical trials, both of which involved adults with Parkinson’s who were experiencing off episodes on levodopa-based regimens.
Both studies lasted about six months, and were mainly designed to evaluate changes in daily on time — periods of good motor symptom control — without troublesome dyskinesia.
- Â Study 016 (NCT01187966) showed that Xadago, at a daily dose of 50 or 100 mg, significantly decreased daily off time while increasing on time without bothersome dyskinesia compared with a placebo. Motor symptom severity was also reduced.
- SETTLE (NCT00627640) showed that Xadago — started at a dose of 50 mg and increased to 100 mg if tolerated — significantly increased daily on time without troublesome dyskinesia compared with a placebo. That was accompanied by decreases in daily off time and improved motor function.
Xadago side effects
The most common side effects associated with Xadago are:
- new or worsening dyskinesia
- falls
- nausea
- insomnia, or trouble sleeping
Xadago also comes with warnings for less common, but potentially serious side effects including:
- new or worsening high blood pressure, especially if taken with certain foods or medications
- excessive drowsiness or falling asleep during daily activities
- hallucinations or psychotic-like behavior
- problems with impulse control or compulsive behaviors
- eye problems
Patients will be monitored for these complications, and if they occur, a doctor may recommend lowering Xadago’s dose or discontinuing treatment. Suddenly stopping Xadago can lead to serious side effects, including high fever and confusion. If discontinuation is necessary, the dose should be tapered under medical supervision.
When used with certain other medications, Xadago could cause a life-threatening complication called serotonin syndrome, in which too much of the brain chemical serotonin accumulates. Because of these and other potential Xadago drug interactions, patients should tell their care providers about all other medications they are using.
Parkinson's News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.